Health Condition 1: null- Macular Edema Secondary to Branch Retinal Vein occlusion
Conditions
Interventions
Intervention1: Ranibizumab: 0.5 mg intravitreal once in a month for 6 months and then once in 2 months
Control Intervention1: Bevacizumab: 1.25mg intravitreal once in a month for 6 months and then onc
Sponsors
LVPrasad Eye Institute
Eligibility
Inclusion criteria
Inclusion criteria: 1.Center-involved macular edema secondary to BRVO with minimum mean retinal thickness of 250 μm in the central subfield on OCT 2.Adults >= 18 years 3.ETDRS BCVA of 20/40 to 20/320 (73 to 24 letters) in the study eye 4.Men and women of childbearing potential must be willing to utilize adequate contraception and not become pregnant (or have their partner[s] become pregnant during the full course of the study 5.Willing, committed, and able to return for ALL clinic visits and complete all study- related procedures 6.Willingness to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. History of vitreoretinal surgery in the study eye or anticipated within the next 12 months following Day 1 2. Prior episode or bilateral manifestation of RVO 4. Prior panretinal laser photocoagulation or macular laser photocoagulation in the study eye 5. BRVO disease duration 9 months from date of diagnosis 6. Decrease in visual acuity due to causes other than BRVO 7. Only one functional eye even if that eye is otherwise eligible for the study 8. Ocular conditions with a poorer prognosis in the fellow eye than in the study eye 9. History or presence of AMD (dry or wet form) that is considered by the investigator to significantly affect central vision, DME, or diabetic retinopathy, defined as eyes of diabetic subjects with more than one microaneurysm outside the area of the vein occlusion (inclusive of both eyes) 10. Previous use of intraocular corticosteroids in the study eye or use of periocular corticosteroids in the study eye within the 3 months prior to Day 1 11. Previous use of intraocular or periocular corticosteroids in the fellow eye within the 3 months prior to Day 1 12. Previous treatment with anti-angiogenic drugs in the study eye 13. Previous treatment with anti-angiogenic drugs in the fellow eye within the 3 months prior to Day one 14. Iris neovascularization, vitreous hemorrhage, traction retinal detachment, or preretinal fibrosis involving the macula in either the study eye or fellow eye 15. Vitreomacular traction or epiretinal membrane in either the study eye or fellow eye evident biomicroscopically or on OCT that is considered by the investigator to significantly affect central vision 16. Ocular inflammation (including trace or above) or external ocular inflammation in the study eye 17. History of idiopathic or autoimmune uveitis in either eye 18. Structural damage to the center of the macula in either the study eye or fellow eye that is likely to preclude improvement in VA following the resolution of macular edema 19. Concurrent disease in the study eye that would compromise VA or require medical or surgical intervention during the study period 20. Cataract surgery in the study eye within 3 months, yttrium-aluminum-garnet (YAG) laser capsulotomy within the past 2 months, or any other intraocular surgery within the 3 months prior to Day 1 21. Aphakia or absence of the posterior capsule in the study eye 22. Uncontrolled glaucoma, defined as IOP >= 25mmHg on optimal medical regimen, in either the study eye or fellow eye or previous filtration surgery in either the study eye or fellow eye 23. Spherical equivalent of the refractive error in the study eye of more than - 8 diopters myopia (for subjects who have had refractive or cataract surgery in the study eye, preoperative spherical equivalent refractive error of more than - 8 diopters myopia) 24. Evidence at examination of infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye or current treatment for serious systemic infection 25. Any ocular disorders in the study eye that, in the opinion of the Investigator, may confound interpretation of study results 26. Uncontrolled hypertension defined as systolic 180 mmHg or 160 mmHg on 2 consecutive measurements or diastolic 100 mmHg on optimal medical regimen 27. Uncontrolled diabetes melli
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of subjects who gain at least 15 letters in BCVA at Week 24Timepoint: The proportion of subjects who gain at least 15 letters in BCVA at Week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change from baseline in BCVA score at Week 24 2. Change from baseline in central retinal thickness, assessed by OCT, at Week 24 3. Proportion of subjects progressing to anterior segment neovascularization, neovascularization of the optic disc (NVD) or neovascularization of the retina elsewhere (NVE) with or without vitreous hemorrhage requiring sector photocoagulation at Week 24 Timepoint: Week 24 from baseline | — |
Countries
India
Contacts
Public ContactMs Archana Digumarti
L.V. Prasad Eye Institute
Outcome results
None listed